Non-Hodgkin's Lymphoma Clinical Trials in Pittsburgh, Pennsylvania
2 recruitingPittsburgh, Pennsylvania
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Hoffmann-La Roche940 enrolled38 locationsNCT03075696
Recruiting
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Non-Hodgkin's LymphomaMycosis Fungoides
Stanford University2,000 enrolled13 locationsNCT02848274